Open AccessErratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972–1980
Author(s) -
Vanita R. Aroda,
Julio Rosenstock,
Carol Wysham,
Jeffrey Unger,
Diego Bellido,
Guillermo González-Gálvez,
Akiyoshi Takami,
Hailing Guo,
Elisabeth Niemoeller,
Elisabeth Souhami,
Richard M. Bergenstal
Publication year - 2017
Publication title -
diabetes care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.636
H-Index - 363
eISSN - 1935-5548
pISSN - 0149-5992
DOI - 10.2337/dc17-er06d
Subject(s) - medicine , insulin glargine , metformin , lixisenatide , type 2 diabetes , randomized controlled trial , diabetes mellitus , basal insulin , endocrinology , urology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom